NDC product
Candesartan Cilexetil and Hydrochlorothiazide
NDC 0378-3001 · Mylan Pharmaceuticals Inc.
Key facts
| Product NDC | 0378-3001 |
|---|---|
| Proprietary name | Candesartan Cilexetil and Hydrochlorothiazide |
| Nonproprietary name | candesartan cilexetil and hydrochlorothiazide |
| Substances | CANDESARTAN CILEXETIL, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Mylan Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA090704 |
| Pharmacologic classes | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS] |
| Marketing start | Dec 4, 2012 |
| Marketing end | Feb 28, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory